AXA Framlington Biotech R

Quick Stats

Bid Price - Offer Price -
Mid Price USX 96.70 Day Change USX +0.71 (1.55%)
Price Date 7 Dec 2016 Crown Rating 1
Shares Class Inc. Yield 0.00 %
Total Expense Ratio 0.00 Fund Size 556,211,800.00
Launch Date 26/11/2001 Standard Initial Charge (%) 0.00
Currency USX ISA Eligible No
Annual Management Charge (%) 0.00 Sector IMA UK Equity Income
Min Investment (£) 0.00 Total Expense Ratio (%) 0.00
ISIN Min TopUp (£) 0.00

Fund Objective

To provide long-term capital appreciation by investing principally in equity securities of companies in the biotechnology, genomic and medical research industries worldwide.

Fund Managers

Linden Thomson
Linden Thomson joined AXA IM in June 2011 as sector specialist on the Healthcare equity desk. Linden joined AXA IM from Hedge Fund Clear River Capital where she was responsible for fundamental stock research across the global pharmaceutical and biotechnology sectors. Prior to that she worked for Goldman Sachs on the sell side where she was based in the healthcare research team with specific focus on the biotechnology sector. She graduated from Edinburgh University with a BSc in Medical Microbiology and is a CFA Charterholder.